Revitalizing oncology medications access in Saudi Arabia: Current challenges and recommendations by the Saudi Oncology Pharmacy Assembly.

Autor: Alkhudair N; Department of Clinical Pharmacy, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia., Howaidi J; Department of Clinical Pharmacy, King Fahad Medical City, Riyadh, Saudi Arabia., Alnuhait M; Department of Clinical Pharmacy, Umm Al-Qura University, Makkah, Saudi Arabia., Alshamrani M; Pharmaceutical Care Services, Ministry of National Guard Health Affairs, Jeddah, Saudi Arabia., Khan M; Pharmaceutical Care Services, Ministry of National Guard Health Affairs, Jeddah, Saudi Arabia., Alharbi A; Pharmaceutical Care Services, Ministry of National Guard Health Affairs, Jeddah, Saudi Arabia., Alnajjar F; Department of Clinical Pharmacy, King Fahad Medical City, Riyadh, Saudi Arabia., Bajnaid E; Pharmaceutical Care Services Administration, King Abdullah Medical City, Makkah, Saudi Arabia., Almodaheem H; Deputyship of Therapeutic Affairs, Ministry of Health, Riyadh, Saudi Arabia., Alhowimel M; Unified Procurement, National Unified Procurement Company, Riyadh, Saudi Arabia., Alzahrani A; Medical Oncology Department, Comprehensive Cancer Center, King Fahad Medical City, Riyadh, Saudi Arabia., Khardaly A; Deputyship of Therapeutic Affairs, Ministry of Health, Riyadh, Saudi Arabia., Alnahedh M; Pharmaceutical Care Division, King Faisal Specialist Hospital & Research Center, Riyadh, Saudi Arabia., Elsoudi H; Clinical Pharmacy Department, Pharmaceutical Care Services Administration, King Fahad Specialist Hospital, Dammam, Saudi Arabia., Alabdulkareem H; Drug Policy and Economic Center, Ministry of National Guard Health Affairs, Riyadh, Saudi Arabia.; Doctoral School of Applied Informatics and Applied Mathematics, Óbuda University, Budapest, Hungary., Alrashidan A; Corporate pharmaceutical planning, logistic & contracts management, Ministry of National Guard Health Affairs, Riyadh, Saudi Arabia., Alzahrani M; Department of Medicine, College of Medicine, King Saud University, Riyadh, Saudi Arabia., Alrajhi A; Department of Clinical Pharmacy, King Fahad Medical City, Riyadh, Saudi Arabia.; Department of Pharmacy Practice, College of Pharmacy, AlFaisal University, Riyadh, Saudi Arabia.

Publikováno v: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners [J Oncol Pharm Pract] 2024 Feb 20, pp. 10781552241232697. Date of Electronic Publication: 2024 Feb 20.

Real-World Impact of Switching From Insulin Glargine (Lantus ^® ) to Basaglar ^® and Potential Cost Saving in a Large Public Healthcare System in Saudi Arabia.

Autor: AlRuthia Y; Department of Clinical Pharmacy, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.; Pharmacoeconomics Research Unit, Department of Clinical Pharmacy, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia., Bahari OH; Department of Pharmaceutical Care, King Saud Medical City, Riyadh, Saudi Arabia., Alghnam S; King Abdullah International Medical Research Center (KAIMRC), King Saud Bin Abdulaziz University for Health Sciences (KSAU-HS), King Abdulaziz Medical City, National Guard Health Affairs, Riyadh, Saudi Arabia., Alrumaih AM; Pharmaceutical Care Department, Medical Services for Armed Forces, Ministry of Defense, Riyadh, Saudi Arabia., Asiri H; Department of Clinical Pharmacy, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia., Alshammari M; Drug Policy and Economic Center, National Guard Health Affairs, Riyadh, Saudi Arabia., Alhowimel M; National Unified Procurement Company (NUPCO), Riyadh, Saudi Arabia., Al-Abdulkarim HA; King Abdullah International Medical Research Center (KAIMRC), King Saud Bin Abdulaziz University for Health Sciences (KSAU-HS), King Abdulaziz Medical City, National Guard Health Affairs, Riyadh, Saudi Arabia.; Drug Policy and Economic Center, National Guard Health Affairs, Riyadh, Saudi Arabia.

Publikováno v: Frontiers in public health [Front Public Health] 2022 Jun 13; Vol. 10, pp. 852721. Date of Electronic Publication: 2022 Jun 13 (Print Publication: 2022).

PBI12 Budget Impact Analysis of Baricitinib for the Management of Moderate-to-Severe Rheumatoid Arthritis in the Kingdom of Saudi Arabia

Autor: Almodaimegh, H., Alrumaih, A., Alabdulkarim, H.A.A., Alsaqa'aby, M., Alturaiki, A., Erdogan, A., Alhowimel, M., Alhammad, A., El Ojeil, R., Biswas, C.

Publikováno v: In Value in Health December 2020 23 Supplement 2:S412-S412

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.